专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008043601A3 TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASING PROFILE 审中-公开
标题翻译：透皮治疗系统两相释放曲线
公开(公告)号：WO2008043601A3
公开(公告)日：2008-06-12
申请号：PCT/EP2007058867
申请日：2007-08-27
申请人： AXXONIS PHARMA AG , TACK JOHANNES , SCHURAD BJOERN , MUELLER-SCHUBERT ANTJE , HOROWSKI REINHARD
发明人： TACK JOHANNES , SCHURAD BJOERN , MUELLER-SCHUBERT ANTJE , HOROWSKI REINHARD
IPC分类号： A61K9/70 , A61K47/06 , A61K47/10 , A61K47/16 , A61K47/32 , A61K47/44 , C07D457/00
CPC分类号： A61K9/7061 , A61K31/48
摘要： The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherein R 1 represents an H atom or a halogen atom and R 2 an alkyl group with 1 to 4 carbon atoms and ------ a single or double bond, and a removable protective layer, the ergolin compound or the physiologically compatible salt or derivative thereof being stabilized by an antioxidant and a basic polymer. The TTS is characterized in that the matrix contains at least one hydrocarbon having 8 to 18 carbon atoms in a linear or branched chain and carrying a functional group at the end of the alkyl chain, and/or aloe vera oil so that, in a first phase (0-5 hours after application), only 0 to 20 % of the therapeutically desired steady state plasma concentration of the ergolin compound is achieved and, in a second phase (5-20 hours after application), the therapeutically desired steady state plasma concentration of the ergolin compound is achieved.
摘要翻译：本发明涉及一种经皮治疗系统（TTS）由不可渗透的覆盖层的湿润剂，式（I）或其生理上可接受的盐或衍生物矩阵，其中R ^{1 是一个氢原子或一个麦角灵一个卤原子，R ^{2 是具有碳原子数1〜4的烷基，以及-----是单键或双键，和一个可去除的保护层，其中所述麦角灵化合物或生理学上可接受的盐或衍生物的抗氧化剂和碱性聚合物是稳定的。的TTS的特征在于，在基体中，都包括从在烷基链和/或芦荟油的端部携带的官能团在直链或支链8-18个碳原子的具有至少一个烃，使得在第一阶段中只有0-20％的麦角灵化合物的治疗所需的稳态血浆浓度的实现（应用0-5小时后），且仅在一个第二阶段（给药后5-20小时），麦角灵化合物的治疗期望的稳态血浆浓度达到，}}

IPRDB

热门服务

关于我们

友情链接

联系方式